Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-CF113 in the treatment of endometriosis versus placebo after 3 medication cycles followed by 3 open-label medication cycles

Next Previous
X
Search
Trial Profile

A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-CF113 in the treatment of endometriosis versus placebo after 3 medication cycles followed by 3 open-label medication cycles

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Drospirenone (Primary)
  • Indications Endometriosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Chemo Research, S.L.

    • Most Recent Events

    • 12 Jan 2024 This study has been completed in Hungary, according to European Clinical Trials Database record.
    • 20 Oct 2023 This trial has been completed in Slovakia (Global end date: 25 Sep 2023).
    • 07 Oct 2023 This trial has been completed in Germany (Global end date: 25 Sep 2023).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top